The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.
本发明涉及式(Ia)的化合物或药学上可接受的盐、
水合物、溶剂合物、包合物、多晶型、立体异构体,还揭示了包含式(Ia)的化合物的药物组合物以及利用式(Ib)的化合物,特别是用于治疗破坏Rad51-BRCA2相互作用有益的疾病或紊乱的用途。